Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronomodulated vs Routine Chemotherapy in Advanced Nasopharyngeal Cancer
NCT02937519Phase 2Unknown
- Sponsor
- Guizhou Medical University
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Guizhou Medical University. Primary endpoints: Number of Participants with curative effect at 1 year and Number of Participants with Adverse Events as a Measure of Safety at 5 years. Status: unknown.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02937519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937519.